electroCore, Inc. (ECOR) AI Stock Analysis

electroCore, Inc., headquartered in Rockaway, New Jersey, is a medical device company specializing in non-invasive vagus nerve stimulation (nVNS) therapies. The company focuses on developing and commercializing treatments such as gammaCore, its flagship device designed for the acute relief of pain associated with migraine and episodic cluster headache in adults. Its lead device, gammaCore Sapphire, is a rechargeable and reloadable handheld solution built for regular and intermittent use. Founded in 2005, electroCore addresses unmet neurological needs and pursues strategic collaborations with healthcare providers to broaden research, market access, and patient care.

electroCore generated revenue of $32.0M in FY2025, representing revenue growth of 27.2% compared to $25.2M in FY2024 and $16.0M in FY2023. Between FY2020 and FY2025, its 5-year revenue CAGR was 55.7%. Gross margin expanded from 74.6% in FY2021 to 86.8% in FY2025. Operating margin improved from -367.7% in FY2021 to -41.1% in FY2025, while net margin improved from -315.9% to -43.6%. In FY2025, net income was -$14.0M and EPS was -$1.65. For the trailing twelve months ended June 30, 2026, revenue reached $37.0M, with quarterly revenue growth of 28.0% year-over-year and an operating margin of -29.3%.

As of June 30, 2026, electroCore held $10.0M in cash and short-term investments and $9.6M in total debt, leaving net cash of $481,000. Total assets were $17.1M against shareholders' equity of -$2.8M, with a current ratio of 1.21. For FY2025, operating cash flow was -$8.2M and free cash flow was -$8.3M, while capital expenditures totaled $66,000. Over five years, the company's share count change was 99.6%.

At a last close of $7.85 on October 16, 2026, electroCore has a market capitalization of $70.8M and an enterprise value of $102.6M. The stock trades at a price-to-sales ratio of 1.9x, compared to 4.1x for the median of its US-listed Healthcare peers. Its forward P/E is 384.6x compared to the peer median of 17.3x, and its EV-to-EBITDA is 0.2x compared to the peer median of 12.0x. Over the past year, ECOR delivered a return of 56.4%, outperforming the SPY return of 16.8%, though its 5-year return of -47.5% lagged the SPY return of 83.0%.

Wall Street coverage comprises 4 Strong Buy ratings and 1 Buy rating, with no Hold, Sell, or Strong Sell ratings. The mean price target is $19.17, representing an upside of 144.2% versus the last close of $7.85. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $41.9M and an EPS of -$1.38. For the next fiscal year, 4 analysts estimate revenue of $54.4M and an EPS of -$0.62. electroCore has beaten EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 4, 2026.

This page is an AI-written research summary of electroCore, Inc. (ECOR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ECOR income statement, ECOR balance sheet, ECOR key metrics, ECOR analyst forecast, ECOR chart. See the ECOR stock overview for the latest quote and news.